Login / Signup

Letermovir for Cytomegalovirus Prevention in Adolescent Patients Following Hematopoietic Cell Transplantation.

Nicole P DaukshusAnthony CirincioneMolly SiverSherry MathewBinni KunvarjeeAmelia ChanJaap Jan BoelensSusan K SeoGenovefa A PapanicolaouNancy A Kernan
Published in: Journal of the Pediatric Infectious Diseases Society (2022)
There are limited data for letermovir as primary cytomegalovirus (CMV) prophylaxis in patients less than 18 years of age. We report 9 adolescent patients who received letermovir following hematopoietic cell transplantation. No patients developed clinically significant CMV while taking letermovir. Letermovir was well tolerated and efficacious in preventing CMV infections.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • chronic kidney disease
  • newly diagnosed
  • prognostic factors
  • mental health
  • epstein barr virus
  • patient reported outcomes